drugset

drugset / Trial / NCT01144260

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01144260 ↗

Phase 2 Completed 20 enrolled CytRx

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Timeline

Start: 2010-06
Primary completion: 2011-12
Completion: 2013-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bafetinib	Small molecule	250 mg	Oral

Indications